<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00174967</url>
  </required_header>
  <id_info>
    <org_study_id>TMX-00-004</org_study_id>
    <secondary_id>U1111-1114-1992</secondary_id>
    <nct_id>NCT00174967</nct_id>
  </id_info>
  <brief_title>Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout</brief_title>
  <official_title>Phase II, Dose-Response, Safety and Efficacy Study of Oral TMX-67 in Subjects With Gout.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of febuxostat, once daily (QD), in
      reducing serum urate levels in subjects with gout.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gout is a chronic urate crystal deposition disorder, which if left untreated may result in
      progressive disease characterized by joint and bone destruction from tophaceous deposits and
      renal impairment due to gouty nephropathy. Hyperuricemia, defined as a serum urate
      concentration of &gt;7.0 milligrams per deciliter (mg/dL), is the underlying metabolic
      aberration leading to urate crystal deposition in gout. Gout has several clinical
      presentations, including: recurrent acute attacks of inflammatory arthritis; deposition of
      monosodium urate monohydrate crystals in joints, bones and even parenchymal organs
      (tophaceous gout); renal impairment; and uric acid nephrolithiasis. As serum urate levels
      increase beyond &gt;7.0 mg/dL, the risks for gouty arthritis or for renal calculi increase.

      Currently allopurinol is the only xanthine oxidase inhibitor available. Allopurinol is the
      agent of choice for reduction of serum urate levels in patients with: uric acid
      overproduction; unresponsive or intolerant to uricosuric agents; impaired renal function;
      uric acid urolithiasis; or tophi.

      Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as
      an orally administered agent for management of hyperuricemia in patients with gout.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <completion_date type="Actual">July 2001</completion_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Level Decreased to &lt;6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit.</measure>
    <time_frame>Day 28.</time_frame>
    <description>Serum urate values were obtained at the Day 28 visit. The percentage of subjects whose serum urate decreased to &lt;6.0 mg/dL at the Day 28 visit was summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Level Decreased to &lt;6.0 mg/dL at the Day 7 Visit.</measure>
    <time_frame>Day 7.</time_frame>
    <description>Serum urate values were obtained at the Day 7 visit. The percentage of subjects whose serum urate decreased to &lt;6.0 mg/dL at the Day 7 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Level Decreased to &lt;6.0 mg/dL at the Day 14 Visit.</measure>
    <time_frame>Day 14.</time_frame>
    <description>Serum urate values were obtained at the Day 14 visit. The percentage of subjects whose serum urate decreased to &lt;6.0 mg/dL at the Day 14 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Whose Serum Urate Level Decreased to &lt;6.0 mg/dL at the Day 21 Visit.</measure>
    <time_frame>Day 21.</time_frame>
    <description>Serum urate values were obtained at the Day 21 visit. The percentage of subjects whose serum urate decreased to &lt;6.0 mg/dL at the Day 21 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Urate Levels From Baseline to the Day 7 Visit.</measure>
    <time_frame>Baseline and Day 7.</time_frame>
    <description>Serum urate values were obtained at the Day 7 visit. The percent change in serum urate from baseline to the Day 7 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Urate Levels From Baseline to the Day 14 Visit.</measure>
    <time_frame>Baseline and Day 14.</time_frame>
    <description>Serum urate values were obtained at the Day 14 visit. The percent change in serum urate from baseline to the Day 14 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Urate Levels From Baseline to the Day 21 Visit</measure>
    <time_frame>Baseline and Day 21.</time_frame>
    <description>Serum urate values were obtained at the Day 21 visit. The percent change in serum urate from baseline to the Day 21 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Urate Levels From Baseline to the Day 28 Visit.</measure>
    <time_frame>Baseline and Day 28.</time_frame>
    <description>Serum urate values were obtained at the Day 28 visit. The percent change in serum urate from baseline to the Day 28 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Percent Change in Serum Urate Level From Baseline During the Entire Treatment Period.</measure>
    <time_frame>Baseline and Any visit (Day 7, 14, 21,or 28)</time_frame>
    <description>Serum urate values were obtained at the Day 7, 14, 21,and 28 visits. The maximum percent change in serum urate levels obtained at any visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in 24-hour Urine Uric Acid Level From Baseline to Day 28.</measure>
    <time_frame>Baseline and Day 28.</time_frame>
    <description>24-hour urine uric acid levels were obtained at the Day 28 visit. The percent change in 24-hour urine uric acid level from baseline to the Day 28 visit was summarized.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Placebo QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat 40 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat 80 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat 120 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.</description>
    <arm_group_label>Placebo QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.</description>
    <arm_group_label>Febuxostat 40 mg QD</arm_group_label>
    <other_name>TMX-67</other_name>
    <other_name>Tei-6720</other_name>
    <other_name>Uloric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.</description>
    <arm_group_label>Febuxostat 80 mg QD</arm_group_label>
    <other_name>TMX-67</other_name>
    <other_name>Tei-6720</other_name>
    <other_name>Uloric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.</description>
    <arm_group_label>Febuxostat 120 mg QD</arm_group_label>
    <other_name>TMX-67</other_name>
    <other_name>Tei-6720</other_name>
    <other_name>Uloric</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hyperuricemia (serum uric acid â‰¥8.0 mg/dL).

          -  Must meet American College of Rheumatology criteria for gout.

          -  Must have adequate renal function (serum creatinine &lt;1.5 mg/dL).

          -  Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout the
             duration of the study.

        Exclusion Criteria:

          -  History of xanthinuria

          -  Alcohol consumption &gt;14/week

          -  Has a history of significant concomitant illness.

          -  Has active liver disease.

          -  Has a body mass index greater than 50 kilogram per meterÂ² (kg/mÂ²)

          -  Any other significant medical condition that would interfere with the treatment,
             safety or compliance with the protocol, as defined by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <link>
    <url>http://general.takedapharm.com/content/file.aspx?applicationcode=6C7C39D8-5D09-453B-BF30-696A4AB88E62&amp;fileTypeCode=ULORICPI</url>
    <description>Uloric Package Insert</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <results_reference>
    <citation>Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005 Mar;52(3):916-23.</citation>
    <PMID>15751090</PMID>
  </results_reference>
  <results_reference>
    <citation>Colwell HH, Hunt BJ, Pasta DJ, Palo WA, Mathias SD, Joseph-Ridge N. Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness. Int J Clin Pract. 2006 Oct;60(10):1210-7. Epub 2006 Aug 15.</citation>
    <PMID>16911575</PMID>
  </results_reference>
  <results_reference>
    <citation>Goldfarb DS, MacDonald PA, Hunt B, Gunawardhana L. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. J Rheumatol. 2011 Jul;38(7):1385-9. doi: 10.3899/jrheum.101156. Epub 2011 May 15.</citation>
    <PMID>21572152</PMID>
  </results_reference>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>March 12, 2009</results_first_submitted>
  <results_first_submitted_qc>May 26, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2009</results_first_posted>
  <last_update_submitted>July 27, 2011</last_update_submitted>
  <last_update_submitted_qc>July 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sr. VP, Clinical Science</name_title>
    <organization>Takeda Global Research &amp; Development Center, Inc.</organization>
  </responsible_party>
  <keyword>Uric Acid</keyword>
  <keyword>xanthine oxidase</keyword>
  <keyword>tophi</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 24 investigative sites from 31 January 2001 to 9 July 2001</recruitment_details>
      <pre_assignment_details>Participants currently receiving urate-lowering therapy discontinued those urate-lowering therapies and initiated prophylactic medications before enrollemnt in once daily (QD) treatment groups. All other subjects also initiated prophylactic medications.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Febuxostat 40 mg QD</title>
          <description>Febuxostat 40 mg, orally, once daily.</description>
        </group>
        <group group_id="P2">
          <title>Febuxostat 80 mg QD</title>
          <description>Febuxostat 80 mg, orally, once daily.</description>
        </group>
        <group group_id="P3">
          <title>Febuxostat 120 mg QD</title>
          <description>Febuxostat 120 mg, orally, once daily.</description>
        </group>
        <group group_id="P4">
          <title>Placebo QD</title>
          <description>Placebo, orally, once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Gout Flare</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Febuxostat 40 mg QD</title>
          <description>Febuxostat 40 mg, orally, once daily.</description>
        </group>
        <group group_id="B2">
          <title>Febuxostat 80 mg QD</title>
          <description>Febuxostat 80 mg, orally, once daily.</description>
        </group>
        <group group_id="B3">
          <title>Febuxostat 120 mg QD</title>
          <description>Febuxostat 120 mg, orally, once daily.</description>
        </group>
        <group group_id="B4">
          <title>Placebo QD</title>
          <description>Placebo, orally, once daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="38"/>
            <count group_id="B5" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.2" spread="14.04"/>
                    <measurement group_id="B2" value="55.2" spread="13.09"/>
                    <measurement group_id="B3" value="56.2" spread="10.83"/>
                    <measurement group_id="B4" value="52.4" spread="12.63"/>
                    <measurement group_id="B5" value="54.0" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 years to &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>â‰¤25 kilogram per meterÂ² (kg/mÂ²)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;25 kg/mÂ² to 30 kg/mÂ²</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;30 kg/mÂ² to 35 kg/mÂ²</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;35 kg/mÂ² to 40 kg/mÂ²</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;40 kg/mÂ²</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Whose Serum Urate Level Decreased to &lt;6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit.</title>
        <description>Serum urate values were obtained at the Day 28 visit. The percentage of subjects whose serum urate decreased to &lt;6.0 mg/dL at the Day 28 visit was summarized.</description>
        <time_frame>Day 28.</time_frame>
        <population>Analysis performed on intent-to-treat (ITT) subjects, defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥8.0 mg/dL. The last observation carried forward (LOCF) method was used to impute missing data. The baseline value was carried forward if no postbaseline visits were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily.</description>
          </group>
          <group group_id="O4">
            <title>Placebo QD</title>
            <description>Placebo, orally, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Level Decreased to &lt;6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit.</title>
          <description>Serum urate values were obtained at the Day 28 visit. The percentage of subjects whose serum urate decreased to &lt;6.0 mg/dL at the Day 28 visit was summarized.</description>
          <population>Analysis performed on intent-to-treat (ITT) subjects, defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥8.0 mg/dL. The last observation carried forward (LOCF) method was used to impute missing data. The baseline value was carried forward if no postbaseline visits were available.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisherâ€™s exact test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisherâ€™s exact test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisherâ€™s exact test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Whose Serum Urate Level Decreased to &lt;6.0 mg/dL at the Day 7 Visit.</title>
        <description>Serum urate values were obtained at the Day 7 visit. The percentage of subjects whose serum urate decreased to &lt;6.0 mg/dL at the Day 7 visit was summarized.</description>
        <time_frame>Day 7.</time_frame>
        <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. The LOCF method was used to impute missing data. The baseline value was carried forward if no post-baseline visits were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily.</description>
          </group>
          <group group_id="O4">
            <title>Placebo QD</title>
            <description>Placebo, orally, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Level Decreased to &lt;6.0 mg/dL at the Day 7 Visit.</title>
          <description>Serum urate values were obtained at the Day 7 visit. The percentage of subjects whose serum urate decreased to &lt;6.0 mg/dL at the Day 7 visit was summarized.</description>
          <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. The LOCF method was used to impute missing data. The baseline value was carried forward if no post-baseline visits were available.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="91"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisherâ€™s exact test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisherâ€™s exact test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisherâ€™s exact test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Whose Serum Urate Level Decreased to &lt;6.0 mg/dL at the Day 14 Visit.</title>
        <description>Serum urate values were obtained at the Day 14 visit. The percentage of subjects whose serum urate decreased to &lt;6.0 mg/dL at the Day 14 visit was summarized.</description>
        <time_frame>Day 14.</time_frame>
        <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. The LOCF method was used to impute missing data. The baseline value was carried forward if no post-baseline visits were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily.</description>
          </group>
          <group group_id="O4">
            <title>Placebo QD</title>
            <description>Placebo, orally, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Level Decreased to &lt;6.0 mg/dL at the Day 14 Visit.</title>
          <description>Serum urate values were obtained at the Day 14 visit. The percentage of subjects whose serum urate decreased to &lt;6.0 mg/dL at the Day 14 visit was summarized.</description>
          <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. The LOCF method was used to impute missing data. The baseline value was carried forward if no post-baseline visits were available.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisherâ€™s exact test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisherâ€™s exact test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisherâ€™s exact test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Whose Serum Urate Level Decreased to &lt;6.0 mg/dL at the Day 21 Visit.</title>
        <description>Serum urate values were obtained at the Day 21 visit. The percentage of subjects whose serum urate decreased to &lt;6.0 mg/dL at the Day 21 visit was summarized.</description>
        <time_frame>Day 21.</time_frame>
        <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. The LOCF method was used to impute missing data. The baseline value was carried forward if no post-baseline visits were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily.</description>
          </group>
          <group group_id="O4">
            <title>Placebo QD</title>
            <description>Placebo, orally, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Whose Serum Urate Level Decreased to &lt;6.0 mg/dL at the Day 21 Visit.</title>
          <description>Serum urate values were obtained at the Day 21 visit. The percentage of subjects whose serum urate decreased to &lt;6.0 mg/dL at the Day 21 visit was summarized.</description>
          <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. The LOCF method was used to impute missing data. The baseline value was carried forward if no post-baseline visits were available.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisherâ€™s exact test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisherâ€™s exact test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisherâ€™s exact test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Serum Urate Levels From Baseline to the Day 7 Visit.</title>
        <description>Serum urate values were obtained at the Day 7 visit. The percent change in serum urate from baseline to the Day 7 visit was summarized.</description>
        <time_frame>Baseline and Day 7.</time_frame>
        <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. The LOCF method was used to impute missing data. The baseline value was carried forward if no post-baseline visits were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily.</description>
          </group>
          <group group_id="O4">
            <title>Placebo QD</title>
            <description>Placebo, orally, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Urate Levels From Baseline to the Day 7 Visit.</title>
          <description>Serum urate values were obtained at the Day 7 visit. The percent change in serum urate from baseline to the Day 7 visit was summarized.</description>
          <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. The LOCF method was used to impute missing data. The baseline value was carried forward if no post-baseline visits were available.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.0" spread="9.67"/>
                    <measurement group_id="O2" value="-39.2" spread="15.9"/>
                    <measurement group_id="O3" value="-53.44" spread="12.3"/>
                    <measurement group_id="O4" value="0.71" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Serum Urate Levels From Baseline to the Day 14 Visit.</title>
        <description>Serum urate values were obtained at the Day 14 visit. The percent change in serum urate from baseline to the Day 14 visit was summarized.</description>
        <time_frame>Baseline and Day 14.</time_frame>
        <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. The LOCF method was used to impute missing data. The baseline value was carried forward if no post-baseline visits were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily.</description>
          </group>
          <group group_id="O4">
            <title>Placebo QD</title>
            <description>Placebo, orally, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Urate Levels From Baseline to the Day 14 Visit.</title>
          <description>Serum urate values were obtained at the Day 14 visit. The percent change in serum urate from baseline to the Day 14 visit was summarized.</description>
          <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. The LOCF method was used to impute missing data. The baseline value was carried forward if no post-baseline visits were available.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.1" spread="11.70"/>
                    <measurement group_id="O2" value="-41.8" spread="14.63"/>
                    <measurement group_id="O3" value="-56.9" spread="8.36"/>
                    <measurement group_id="O4" value="1.62" spread="10.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Serum Urate Levels From Baseline to the Day 21 Visit</title>
        <description>Serum urate values were obtained at the Day 21 visit. The percent change in serum urate from baseline to the Day 21 visit was summarized.</description>
        <time_frame>Baseline and Day 21.</time_frame>
        <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. The last observation carried forward (LOCF) method was used to impute missing data. The baseline value was carried forward if no post-baseline visits were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily.</description>
          </group>
          <group group_id="O4">
            <title>Placebo QD</title>
            <description>Placebo, orally, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Urate Levels From Baseline to the Day 21 Visit</title>
          <description>Serum urate values were obtained at the Day 21 visit. The percent change in serum urate from baseline to the Day 21 visit was summarized.</description>
          <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. The last observation carried forward (LOCF) method was used to impute missing data. The baseline value was carried forward if no post-baseline visits were available.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.3" spread="11.30"/>
                    <measurement group_id="O2" value="-43.9" spread="16.3"/>
                    <measurement group_id="O3" value="-59.4" spread="7.58"/>
                    <measurement group_id="O4" value="-0.57" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Serum Urate Levels From Baseline to the Day 28 Visit.</title>
        <description>Serum urate values were obtained at the Day 28 visit. The percent change in serum urate from baseline to the Day 28 visit was summarized.</description>
        <time_frame>Baseline and Day 28.</time_frame>
        <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. The LOCF method was used to impute missing data. The baseline value was carried forward if no post-baseline visits were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily.</description>
          </group>
          <group group_id="O4">
            <title>Placebo QD</title>
            <description>Placebo, orally, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Serum Urate Levels From Baseline to the Day 28 Visit.</title>
          <description>Serum urate values were obtained at the Day 28 visit. The percent change in serum urate from baseline to the Day 28 visit was summarized.</description>
          <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. The LOCF method was used to impute missing data. The baseline value was carried forward if no post-baseline visits were available.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.6" spread="12.07"/>
                    <measurement group_id="O2" value="-44.3" spread="17.53"/>
                    <measurement group_id="O3" value="-59.1" spread="9.92"/>
                    <measurement group_id="O4" value="-2.2" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Percent Change in Serum Urate Level From Baseline During the Entire Treatment Period.</title>
        <description>Serum urate values were obtained at the Day 7, 14, 21,and 28 visits. The maximum percent change in serum urate levels obtained at any visit was summarized.</description>
        <time_frame>Baseline and Any visit (Day 7, 14, 21,or 28)</time_frame>
        <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily.</description>
          </group>
          <group group_id="O4">
            <title>Placebo QD</title>
            <description>Placebo, orally, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Percent Change in Serum Urate Level From Baseline During the Entire Treatment Period.</title>
          <description>Serum urate values were obtained at the Day 7, 14, 21,and 28 visits. The maximum percent change in serum urate levels obtained at any visit was summarized.</description>
          <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" spread="10.04"/>
                    <measurement group_id="O2" value="49.2" spread="13.24"/>
                    <measurement group_id="O3" value="62.8" spread="7.05"/>
                    <measurement group_id="O4" value="10.0" spread="11.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in 24-hour Urine Uric Acid Level From Baseline to Day 28.</title>
        <description>24-hour urine uric acid levels were obtained at the Day 28 visit. The percent change in 24-hour urine uric acid level from baseline to the Day 28 visit was summarized.</description>
        <time_frame>Baseline and Day 28.</time_frame>
        <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. Missing data was not imputed</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 40 mg QD</title>
            <description>Febuxostat 40 mg, orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily.</description>
          </group>
          <group group_id="O3">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily.</description>
          </group>
          <group group_id="O4">
            <title>Placebo QD</title>
            <description>Placebo, orally, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in 24-hour Urine Uric Acid Level From Baseline to Day 28.</title>
          <description>24-hour urine uric acid levels were obtained at the Day 28 visit. The percent change in 24-hour urine uric acid level from baseline to the Day 28 visit was summarized.</description>
          <population>The analysis was performed on ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had baseline serum urate â‰¥ 8.0 mg/dL. Missing data was not imputed</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.6" spread="28.9"/>
                    <measurement group_id="O2" value="-46.5" spread="27.0"/>
                    <measurement group_id="O3" value="-45.7" spread="30.1"/>
                    <measurement group_id="O4" value="5.9" spread="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochbergâ€™s procedure.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Febuxostat 40 mg QD</title>
          <description>Febuxostat 40 mg, orally, once daily.</description>
        </group>
        <group group_id="E2">
          <title>Febuxostat 80 mg QD</title>
          <description>Febuxostat 80 mg, orally, once daily.</description>
        </group>
        <group group_id="E3">
          <title>Febuxostat 120 mg QD</title>
          <description>Febuxostat 120 mg, orally, once daily.</description>
        </group>
        <group group_id="E4">
          <title>Placebo QD</title>
          <description>Placebo, orally, once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>COSTART</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Guillian Barre Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>COSTART</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Flu Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver Function Tests Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. VP, Clinical Science</name_or_title>
      <organization>Takeda Global Research &amp; Development Center, Inc.</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

